News

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...
On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for ...
How Do Unusual Items Influence Profit? For anyone who wants to understand Pfizer's profit beyond the statutory numbers, it's ...
Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.
Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...
“These results from EV-303 represent a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer, demonstrating the potential of PADCEV in combination with KEYTRUDA when used ...
For some context, during those same three years, the S&P 500 index of 500 of America's biggest companies averaged gains of roughly 17% per year, turning $1,000 into $1,615. Where to invest $1,000 ...
Pfizer Inc. (NYSE:PFE) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Pfizer Inc. (NYSE:PFE) reported ...
A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...
Here are two beaten-down stocks that long-term investors might want to consider buying on the dip and holding for several ...
Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...
Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...